alexa High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.


Journal of Clinical & Experimental Dermatology Research

Author(s): Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, , Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE,

Abstract Share this page

Abstract Thyroid papillary cancers (PTCs) are associated with activating mutations of genes coding for RET or TRK tyrosine kinase receptors, as well as of RAS genes. Activating mutations of BRAF were reported recently in most melanomas and a small proportion of colorectal tumors. Here we show that a somatic mutation of BRAF, V599E, is the most common genetic change in PTCs (28 of 78; 35.8\%). BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46). Moreover, there was no overlap between PTC with RET/PTC, BRAF, or RAS mutations, which altogether were present in 66\% of cases. The lack of concordance for these mutations was highly unlikely to be a chance occurrence. Because these signaling proteins function along the same pathway in thyroid cells, this represents a unique paradigm of human tumorigenesis through mutation of three signaling effectors lying in tandem.
This article was published in Cancer Res and referenced in Journal of Clinical & Experimental Dermatology Research

Relevant Expert PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version